Stockwatch: MS - not a zero sum game
This article was originally published in Scrip
As the first full week of the first quarter 2011 earnings season got underway, lacklustre results from Gilead Sciences, Abbott and Lilly were relegated to the shade by Biogen Idec’s quarterly announcement on 21 April resulting in its stock rising by more than 15%, adding $4 billion to its market cap.
You may also be interested in...
As industry bellwether J&J kicked-off 2019 fourth-quarter and full-year earnings season for life sciences companies, its financial results left investors feeling the cold. But with coronavirus envy sweeping a raft of smaller biotech companies, J&J may have the last laugh.
Stock market reaction to the first day’s news from the 38th J.P. Morgan Healthcare conference in San Francisco was negative, probably because expectations for a continuation of December’s bumper M&A bonanza were too high.
With the 38th J.P. Morgan Healthcare conference about to start in San Francisco, expectations in the investment community are naturally high. This is after a year when the NASDAQ Biotech Index approached its 2015 all-time high, fueled by the acquisitions of biotech companies by pharma companies.